Evidence map›Paper›PMID 40705142›Full record

ArticleNeurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology2025

Central nervous system demyelination associated with biological agents used in the treatment of rheumatologic diseases: a retrospective cohort study.

Doruk Arslan, Basak Sayinalp-Arslan, Emre Bilgin, Pinar Acar-Ozen, Rahsan Gocmen, Ihsan Ertenli, Sedat Kiraz, Rana Karabudak, Umut Kalyoncu, Asli Tuncer

Abstract read
PubMed Publisher
In one paragraph

Article in Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Doruk ArslanDepartment of Neurology, School of Medicine, Hacettepe University, Ankara, Türkiye.
Basak Sayinalp-ArslanDepartment of Internal Medicine, School of Medicine, Hacettepe University, Ankara, Türkiye.
Emre BilginDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Sakarya University, Sakarya, Türkiye.
Pinar Acar-OzenDepartment of Neurology, School of Medicine, Hacettepe University, Ankara, Türkiye.
Rahsan GocmenDepartment of Radiology, School of Medicine, Hacettepe University, Ankara, Türkiye.
Ihsan ErtenliDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Hacettepe University, Ankara, Türkiye.
Sedat KirazDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Hacettepe University, Ankara, Türkiye.
Rana KarabudakDepartment of Neurology, School of Medicine, Hacettepe University, Ankara, Türkiye.
Umut KalyoncuDivision of Rheumatology, Department of Internal Medicine, School of Medicine, Hacettepe University, Ankara, Türkiye.
Asli TuncerDepartment of Neurology, School of Medicine, Hacettepe University, Ankara, Türkiye. maslituncer@gmail.com.ORCID http://orcid.org/0000-0001-9449-4483

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the annual incidence rate and clinical characteristics of central nervous system (CNS) demyelinating disease in patients who receive biologic agents for rheumatic diseases.

methodsPatients who received biologic agents due to rheumatic diseases were identified in a retrospective manner and data of the patients who developed CNS demyelinating disease were recorded.

results4838 out of 5926 patients who attended regular follow-up visits, were included in the study. CNS demyelinating disease was observed in 7 patients for 19.391 patient-years. 4 of 7 were diagnosed with multiple sclerosis (MS). 6 out of 7 were under anti-TNF therapy and mean duration was 13 months under causative drugs. While annual incidence rate of CNS demyelinating disease was 36.1/100000 (95% CI: 17-75), annual multiple sclerosis incidence rate in rheumatologic patients exposed to biologic agents was 19.6/100000 (95% confidence interval 7-52).

conclusionWhen compared with the data obtained in our cohort with annual incidence rates of multiple sclerosis in Europe, it is possible to conclude that there is an increase in the incidence of demyelinating events. Therefore, clinicians must be aware of neurological signs and symptoms in patients who receive biologic agents.

Indexed as

Biological FactorsDemyelinating DiseasesRheumatic DiseasesAdultAgedCohort StudiesFemaleHumansIncidenceMaleMiddle AgedMultiple SclerosisRetrospective StudiesYoung AdultBiological FactorsAnti-TNF therapyCentral demyelinationIncidence rateMultiple sclerosis

Identifiers

PMID40705142

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.